The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies； methods of making such antibodies； fragments, variants, and derivatives of the antibodies； pharmaceutical compositions comprising the same.
